Cancer Treatment Today

Everolimus is an oral antineoplastic agent that targets the raptor mammalian target of rapamycin (mTORC1). The phosphatidylinositol 3-kinase/mTOR signal transduction pathway has been demonstrated to be activated in Hodgkin lymphoma (HL) and there was speculation that everolimus might be effective for this disease. Johnston et al studied everolimus in 19 patient. Patients had received a median of six prior therapies (range, 3-14) and 84% had undergone

Current chemotherapy drugs are very effective for Hodgkin's  lymphomas but patients who relapse after receiving them don;t do as well. This is because the cancers develop resistance to the se drugs. Zolinza is a new drug approved in the USA for the treatment of cutaneous(skin) T-cell lymphoma who have progressive, persistent or recurrent disease  or following two systemic therapies. It may be effective for Hodgkin's. For Hodgkin's, a phase

Current front-line chemotherapy drugs are very effective against Hodgkin's  lymphoma but patients who relapse after receiving them are less likely to achieve long-term, disease-free survival with current salvage therapies. This is because Hodgkin's develops resistance to the drugs or the tumor's biology changes in some way to reduce their effectiveness. This led to researchers testing newly released drugs for this purpose. Zolinza is approved